Should Patients With High-Risk SMM Be Treated Outside a Clinical Trial? No

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Should Patients With High-Risk SMM Be Treated Outside a Clinical Trial? No

By Scripps Health FEATURING Morie Gertz

521 views

March 29, 2024

Comments 0

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

New Approval for Frontline Consolidation in Patients with CD19-posit…

Feat. J. Mccloskey

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

631 views

4 months ago

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

Fred Hutch 14th Annual Comprehensive Hematology & Oncology Review Course

M. Kwok

402 views

3 months ago

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Insights from 2023 ASH Annual Meeting

R. Banerjee

870 views

9 months ago

Why We Should Not Treat SMM

PleXus Communications

B. Derman

444 views

11 months ago

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Indy Hematology Review

M. Gertz

714 views

1 year ago

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Insights from 2023 ASH Annual Meeting

O. Landgren

284 views

11 months ago

Emerging and Current Treatment of MM: What Should We Know and What S…

Indy Hematology Review

K. Anderson

652 views

1 year ago

Myeloma in 2023: So Many Drugs, Yet So Few Cures

Yale Cancer Center

A. Chari

525 views

1 year ago

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

5th SOHO Italy Annual Conference

K. Anderson

251 views

11 months ago

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Dana-Farber Cancer Institute

Y. Liu

90 views

4 months ago

Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussi…

GRACE

A. Goodman, A. Taneja, T. Phillips

133 views

8 months ago

Management of Smoldering Myeloma

XV Eurasian Hematology-Oncology Congress - EHOC 2024

C. Cerchione

60 views

2 months ago

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering Multi…

Insights from 2023 ASH Annual Meeting

S. Thorsteinsdottir

165 views

11 months ago

SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait

SOHO 2023 Eleventh Annual Meeting

A. Dispenzieri

117 views

1 year ago

New

Smoldering Myeloma: If and When to Treat

Victor Jimenez Zepeda

48 views

3 weeks ago

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

5th SOHO Italy Annual Conference

I. Ghobrial

84 views

11 months ago

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

SOHO 2022 Tenth Annual Meeting

T. Martin

232 views

2 years ago

Myeloma 2022: Challenges and Path Forward

UChicago Medicine

A. Jakubowiak

557 views

2 years ago

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and Dexam…

Insights from 2023 ASH Annual Meeting

O. Nadeem

92 views

11 months ago

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM

PleXus Communications

N. Antao, P. Hagen

114 views

11 months ago

AUTOPLAY

Login

Login

Join VuMedi

Should Patients With High-Risk SMM Be Treated Outside a Clinical Trial? No

Optimizing the Management of Patients with Polycythemia Vera (PV)

New Approval for Frontline Consolidation in Patients with CD19-posit…

Recommended

Advances in Multiple Myeloma 2024: From Bench to Bedside

Overview of Monoclonal Gammopathies From MGUS to Smoldering Myeloma

ASH 2023 Summary: "Practice Changing Updates in MM, SMM and MGUS Fro…

Why We Should Not Treat SMM

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

ASH 2023 Insights: "CENTAURUS Study Final Analysis - Efficacy & Safe…

Emerging and Current Treatment of MM: What Should We Know and What S…

Myeloma in 2023: So Many Drugs, Yet So Few Cures

SOHO Italy 2023: Multiple Myeloma Cured in 2030 - What Are the Next …

Updates in the Management of SMM/MGUS and the Prevention of Progress…

Oncologists' Guidance on Treating Smoldering Myeloma: Panel Discussi…

Management of Smoldering Myeloma

ASH 2023 Insights: "iStopMM Study - Risk Factors of Smoldering Multi…

SOHO 2023 DEBATE: Smoldering MM - Time to Watch and Wait

Smoldering Myeloma: If and When to Treat

SOHO Italy 2023: Is It Time for a Biomarkers-Driven Approach in Smol…

SOHO 2022: Next Questions for MM in the Coming 5-10 Years

Myeloma 2022: Challenges and Path Forward

ASH 2023 Insights: "Daratumumab, Bortezomib, Lenalidomide, and Dexam…

Myeloma Rounds: Asymptomatic Patient With High-Risk SMM